Analysis identifies a new impurity in mitoxantrone hydrochloride, suggesting the need for purity assessment.
An unknown impurity in mitoxantrone hydrochloride bulk drug was detected by HPLC at levels around 0.5%. This impurity was isolated from a sample of crude mitoxantrone using preparative HPLC and was characterized as 1,4-dihydroxy-5-2-2-hydroxyethyl-amino-ethyl-amino-8-2-bis 2-hydroxyethyl-amino-ethyl-amino-9,10-anthracenedione based on its spectral data (NMR, IR and MS). The origin and structural elucidation of this impurity are discussed in the paper.
No takes yet. Share an insight, caveat, or question.
A 2009 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: